The analysis of first-day returns (underpricing) of venture-backed biotech IPOs reveals that considerable amount of money are left on the table, dwarfing the underwriter fees, and that these large first-day returns are concentrated in hot IPO market, such as the 1999-2000 genomics bubble and more recently in the years 2014-2015.